NDLI: Targeted therapy for melanoma: a primer.

Please wait, while we are loading the content...

Targeted therapy for melanoma: a primer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Davies, Michael A. Gershenwald, Jeffrey E.
Spatial Coverage	United States
Description	Country affiliation: United States Author Affiliation: Davies MA ( Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 7455 Fannin, 1SCRB2.3019, Unit 0904, Houston, TX 77054, USA. mdavies@mdanderson.org)
Abstract	Melanoma is the most aggressive form of skin cancer. Unfortunately, despite recent improvements for some solid tumors, the prevalence and mortality of melanoma continue to increase. The identification of activating mutations in melanoma, combined with a growing appreciation of the different pattern of genetic changes in the anatomically defined melanoma subtypes, has become the focus of a concerted effort to translate these discoveries into personalized therapeutic approaches for this disease. This article reviews the known mutations, amplifications, and deletions in kinase signaling pathways that have been implicated in melanoma; the prevalence of these genetic events in clinicopathologically defined melanoma subtypes; and the results of clinical trials that use targeted therapy approaches to block aberrantly activated pathways resulting from these mutations. The challenges that must be overcome to achieve improved outcomes with targeted therapies in melanoma in the future are also discussed.
File Format	HTM / HTML
ISSN	10553207
e-ISSN	15585042
DOI	10.1016/j.soc.2010.09.003
Journal	Surgical Oncology Clinics of North America
Issue Number	1
Volume Number	20
Language	English
Publisher	Elsevier
Publisher Date	2011-01-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Surgery Discipline Oncology Melanoma Therapy Skin Neoplasms Dna Primers Gene Amplification Gene Deletion Epidemiology Pathology Mutation Phosphotransferases Proto-oncogene Proteins B-raf Proto-oncogene Proteins C-akt Proto-oncogene Proteins C-kit Signal Transduction Translational Medical Research Research Support, N.i.h., Extramural Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Surgery Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Targeting NRAS in melanoma.

A malignus melanoma genetikai sokszínusége és immunológiai jellemzoi a terápiás paletta tükrében.

Molecularly targeted therapies for melanoma.

Assessment of BRAF and KIT mutations in Japanese melanoma patients.

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

Oncogenetics of melanoma: basis for molecular diagnostics and therapy.

Resistance to Raf inhibition in cancer.

Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma.

C-kit-mutated melanomas: the Chinese experience.

Targeted therapy for melanoma: a primer.

Similar Documents

Targeting NRAS in melanoma.

A malignus melanoma genetikai sokszínusége és immunológiai jellemzoi a terápiás paletta tükrében.

Molecularly targeted therapies for melanoma.

Assessment of BRAF and KIT mutations in Japanese melanoma patients.

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

Oncogenetics of melanoma: basis for molecular diagnostics and therapy.

Resistance to Raf inhibition in cancer.

Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma.

C-kit-mutated melanomas: the Chinese experience.

Targeted therapy for melanoma: a primer.